# Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

> **NCT01900665** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 2129 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Solanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01900665
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-10
- **Final completion:** 2017-02
- **Target enrollment:** 2129 (ACTUAL)
- **Why stopped:** Solanezumab did not meet the study's primary endpoint.
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900665, "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01900665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*